Dr. Marty Makary resigned as commissioner of the Food and Drug Administration on Tuesday, ending a turbulent 13-month tenure defined by policy collisions with the White House, Health and Human Services leadership, and nearly every faction inside the Trump coalition with a stake in what the FDA does. His departure marks the fourth high-profile exit from the Trump administration this year, and one of the messiest.
President Trump announced the change on Truth Social, naming Kyle Diamantas, the FDA's top food regulator and a lawyer by training, as acting commissioner. Speaking to reporters Tuesday afternoon, Trump offered a measured farewell.
"He's a great doctor and he was having some difficulty, but he's going to go on, and he's going to do well."
The difficulty, it turns out, ran deep. NBC News reported that a source close to HHS leadership said the FDA's authorization of fruit-flavored vapes for adults last Tuesday triggered Makary's decision to leave. He chose to resign ahead of scheduled congressional testimony on Wednesday rather than publicly defend a position he did not support.
The flavored-vape question had been building for months. Trump vowed during the 2024 presidential campaign to "save" vaping, and the Wall Street Journal reported last week that the president was frustrated Makary had not moved quickly enough to approve flavored e-cigarettes. NBC News separately reported that Trump had been considering removing Makary after months of dissatisfaction with parts of his work at the agency.
Then the FDA authorized the products, and Makary apparently could not stomach defending the move in front of Congress. The timeline is telling: the authorization came last Tuesday, and Makary was gone exactly one week later.
The New York Post reported that a major source of conflict was Makary's slow-walking of flavored e-cigarette approvals, which angered Trump and reportedly led to a direct reprimand. Makary had also made enemies across multiple factions, vape industry allies, rare-disease advocates, anti-abortion activists, and administration officials upset by his staffing and policy decisions.
In his resignation note, Makary kept it brief: "Please accept my resignation, effective today."
The resignation did not happen in a vacuum. AP News reported that the decision to remove Makary was made by Health Secretary Robert F. Kennedy Jr., with the White House signing off. An administration official told AP directly: "The decision to get rid of Makary was made by Kennedy, and then the White House signed off on it."
That detail reframes the departure. Makary may have submitted a resignation letter, but the push came from above. Just The News noted that Politico, which first broke the story, cited an administration official saying Makary's departure came at Kennedy's behest. His tenure was described as tumultuous, with controversies spanning abortion drugs, vape approvals, and the broader Make America Healthy Again movement.
This pattern of personnel shakeups across federal agencies has become a recurring feature of the administration's second term. The question is whether these changes reflect a White House tightening its grip on policy execution or an administration still finding its footing on internal management.
Vapes were the proximate cause, but the abortion pill mifepristone was the other fault line. During his confirmation process, Makary had promised to conduct an FDA review of the drug's safety. The agency never released that report.
Some officials within HHS were pushing Makary to issue tighter restrictions on mifepristone, NBC News reported. Republican lawmakers have been pressing to reverse a Biden-era rule that allows mifepristone to be mailed and dispensed via telehealth rather than only in person.
The Supreme Court earlier this month temporarily allowed mifepristone to continue to be accessible nationwide after a lower court restricted access to in-person patients only. That ruling added urgency to the internal debate, and Makary was caught between competing pressures from social conservatives demanding action and a legal landscape still in flux.
The Washington Examiner reported that Makary had faced recent conflicts over vaping approvals, abortion-pill policy, and pharmaceutical industry disputes, all contributing to pressure on his position. The outlet described him as the latest Trump health official to be ousted during the president's current term.
For pro-life voters who supported Trump in part because of his promises on abortion-related policy, the unfinished mifepristone review is a legitimate concern. Whether Diamantas, a food-regulation lawyer with no public track record on drug policy, will pick up that work remains an open question.
Makary's exit follows a string of senior departures that have marked 2026. Since January, former Homeland Security Secretary Kristi Noem and former Attorney General Pam Bondi have been let go. In April, former Labor Secretary Lori Chavez DeRemer resigned amid a misconduct probe.
Four cabinet-level or equivalent departures in roughly five months is a pace that invites scrutiny. Supporters will note that a president willing to make changes is preferable to one who tolerates underperformance. Critics will argue the churn signals dysfunction. The truth likely sits somewhere in between, but the pattern is hard to ignore.
Across the administration, the push for accountability within federal agencies has been a consistent theme, driven by both the White House and Republican lawmakers on Capitol Hill. Whether that accountability extends to ensuring stable, competent leadership at agencies like the FDA is a fair question for conservatives to ask.
Kyle Diamantas steps into the acting role at a moment when the FDA faces no shortage of challenges. The agency is navigating the mifepristone legal fight, the fallout from flavored-vape authorization, ongoing pharmaceutical industry disputes, and the kind of emerging public-health threats that demand steady institutional leadership.
Dr. Ofer Levy, director of the Precision Vaccines Program at Boston Children's Hospital, said he hopes Makary's replacement is prepared for what lies ahead.
"The challenges to human health are greater than ever. The hantavirus is just one example of how interconnected we are and how one part of the world affects another part of the world."
Diamantas is a lawyer, not a physician, a fact that will matter to both supporters who want a more politically responsive FDA and critics who believe the agency's credibility rests on scientific leadership. His background in food regulation gives him institutional knowledge but not the medical bona fides that Makary, a longtime surgeon at Johns Hopkins Hospital and professor emeritus at the Johns Hopkins School of Medicine, brought to the job.
The broader context of ongoing policy debates within the administration suggests that Trump's second term continues to be defined by a willingness to move quickly, sometimes at the cost of continuity.
Makary's story is not unusual in Washington. A credentialed outsider arrives with reformist energy, runs into the political machinery of an administration with competing priorities, and discovers that the job requires more coalition management than clinical judgment. The vape authorization was the final straw, but the cracks had been forming for months, on mifepristone, on staffing, on the basic question of who the FDA commissioner answers to when the White House, HHS, Congress, and industry lobbyists all want different things.
AP reported that Makary struggled with FDA staff morale and management after mass layoffs, leadership upheaval, and controversies where scientific principles appeared to be overridden by political interests. That description, if accurate, paints a picture of an agency in need of steadier hands, not just a different political orientation.
Conservatives rightly want an FDA that is less captured by bureaucratic inertia and more responsive to elected leadership. But responsiveness without coherence produces exactly the kind of churn that undermines the reforms voters sent this administration to deliver. The broader security and governance challenges facing the administration demand officials who can execute, not just comply.
The FDA regulates roughly a quarter of every dollar Americans spend. It deserves a commissioner who can last long enough to finish the job.
